Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: Adagene and ConjugateBio partner to develop novel antibody drug conjugate Adagene has partnered with ConjugateBio to supply a proprietary antibody for use in bispecific ADC development The […]
Weekly Digest – July 2025 Weekly Digest – July 2025 11 July 2025: Lotte Biologics, Abtis collaborate on next-generation ADC technology development Lotte Biologics and Abtis signed an MOU to co-develop next-generation ADC technologies, integrating Abtis’ AbClick linker platform with […]
Weekly Digest – July 2025 Weekly Digest – July 2025 04 July 2025: InnoCare announces approval of clinical trial of a novel ADC ICP-B794 in China InnoCare Pharma received IND approval from China’s NMPA to begin clinical trials for ICP-B794, […]
Weekly Digest – July 2025 Weekly Digest – July 2025 01 July 2025: Iksuda Therapeutics receives FDA IND clearance for IKS014 The U.S. FDA has cleared Iksuda Therapeutics’ IND application for IKS014, a HER2-targeting ADC, enabling expansion of its ongoing […]
Weekly Digest – July 2025 Weekly Digest – July 2025 01 July 2025: Huadong Medicine’s first-in-class ADC HDM2012 gains FDA Phase I trial clearance Huadong Medicine received FDA clearance to begin a Phase I clinical trial in the U.S. for […]
Weekly Digest – July 2025 Weekly Digest – July 2025 03 July 2025: Elevation Oncology ends license agreement with CSPC Megalith Biopharmaceutical Elevation Oncology has terminated its license agreement with CSPC Megalith Biopharmaceutical for EO-3021, effective June 26, 2025 EO-3021 […]
Weekly Digest – July 2025 Weekly Digest – July 2025 02 July 2025: Biokin, having landed BMS deal, posts Phase 3 cancer win for bispecific ADC Biokins Phase 3 trial of its bispecific ADC, Izalontamab brengitecan (iza-bren), met at least […]
Weekly Digest – July 2025 Weekly Digest – July 2025 03 July 2025: Akeso’s first bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials, strengthening leadership in ‘IO+ADC’ 2.0 strategy Akeso has dosed the first patient in the Phase 1 clinical trial […]
Weekly Digest – June 2025 Weekly Digest – June 2025 23 June 2025: DATROWAY approved in the U.S. as first TROP2 directed therapy for patients with previously treated advanced EGFR-mutated non-small cell lung cancer DATROWAY (datopotamab deruxtecan-dlnk) received accelerated approval in […]
Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: MediLink announces YL201 granted Breakthrough Therapy Designation by FDA The U.S. FDA has granted Breakthrough Therapy Designation to YL201, a B7H3-targeted ADC developed by MediLink Therapeutics, for […]
